Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 19/20 | 0.47 |
| ▸ | FAP | Q12884 | 4/20 | 0.44 |
| ▸ | DPP8 | Q6V1X1 | 4/20 | 0.44 |
| ▸ | DPP9 | Q86TI2 | 4/20 | 0.44 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.42 |
| ▸ | PREP | P48147 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5220299 | 0.92 | DPP4 (0.45) | DPP4FAPDPP8DPP9DPP7 | |
| SCHEMBL5217855 | 0.92 | DPP4 (0.48) | DPP4FAPDPP8DPP9DPP7 | |
| SCHEMBL5667975 | 0.88 | DPP4 (0.51) | DPP4FAPDPP8DPP9DPP7 | |
| SCHEMBL5221879 | 0.88 | DPP4 (0.51) | DPP4FAPDPP8DPP9DPP7 | |
| SCHEMBL5221875 | 0.84 | DPP4 (0.48) | DPP4 | |
| SCHEMBL5217289 | 0.79 | HSD11B1 (0.42) | — | |
| SCHEMBL5221694 | 0.76 | DPP4 (0.48) | DPP4DPP8DPP9DPP7PREP | |
| SCHEMBL1154733 | 0.75 | DPP4 (0.39) | DPP4 | |
| SCHEMBL1155232 | 0.75 | DPP4 (0.39) | DPP4 | |
| SCHEMBL12873129 | 0.75 | DPP4 (0.39) | DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1399433-B1 | FLUOROPYRROLIDINES AS DIPEPTIDYL PEPTIDASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2007-08-22 | — | — | EP | disclosed |
| US-7183290-B2 | Fluoropyrrolidines as dipeptidyl peptidase inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2007-02-27 | — | — | US | disclosed |
| US-20040242636-A1 | Enzyme inhibitors as antiinflammatory ageents for psoriasis, obesity | SMITHKLINE BEECHAM CORPORATION | 2004-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242636-A1 | Enzyme inhibitors as antiinflammatory ageents for psoriasis, obesity | DPP4, DPP7, DPP3 | DPP4 1/4885FAP 9/4885DPP8 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.